| Closed |
S0512 |
BAY 43-9006 in Combination with Carboplatin + Paclitaxel in Metastatic Uveal Melanoma |
3/15/2006 |
1/1/2009 |
56% |
|
Published
|
| Closed |
S0435 |
BAY 43-9006 in Platinum-Treated Extensive SCLC |
7/1/2005 |
2/15/2007 |
100% |
|
Published
|
| Closed |
SWOG-8216/38 |
BCG - Bladder |
12/1/1982 |
1/15/1987 |
|
|
Published
|
| Closed |
S1602 |
BCG Strain Differences and BCG vaccination in High-Grade Non-Muscle Invasive Bladder Cancer |
2/7/2017 |
12/15/2020 |
100% |
|
|
| Closed |
S2101 |
BiCaZO - iMATCH pilot |
10/14/2022 |
|
25% |
|
|
| Closed |
SWOG-9136 |
Biologic Parameters in Soft Tissue Sarcomas: A Companion Study to Select Southwest Oncology Group Clinical Trials with Soft Tissue Sarcoma Patients |
12/15/1991 |
6/15/1998 |
64% |
|
Published
|
| Closed |
SWOG-9000 |
Biomarkers of Colorectal Cancer Prognosis |
2/15/1991 |
9/15/1993 |
67% |
|
Published
|
| Closed |
SWOG-9140 |
Bladder |
12/1/1992 |
12/1/1997 |
100% |
|
Published
|
| Closed |
SWOG-440 |
Bleomycin for Solid Tumors and Lymphomas |
12/11/1970 |
7/1/1971 |
|
|
Published
|
| Closed |
S1221 |
BRAF Mutant Metastatic Cancer |
7/1/2013 |
|
39% |
|
|
| Closed |
SWOG-7811 |
Brain Metastases |
7/24/1978 |
5/11/1982 |
|
|
|
| Closed |
S9832 |
Breast Recurrence |
7/15/1998 |
11/15/2002 |
100% |
|
Published
|
| Closed |
S0300 |
CANCER CONTROL - Premenopausal Women at High Risk for Breast Cancer |
11/1/2004 |
5/13/2008 |
8% |
|
|
| Closed |
S0230 |
CANCER CONTROL - Prevention of Ovarian Failure Following Chemotherapy in Early Stage Breast Cancer |
10/1/2003 |
|
56% |
|
Published
|
| Closed |
S0702 |
CANCER CONTROL: Prospective ONJ Trial |
12/15/2008 |
12/13/2013 |
100% |
|
Published
|
| Closed |
S0342 |
Carbo/Pac + Cetuximab vs. Carbo/Pac followed by Cetuximab/selected IIIB & IV NSCLC |
7/1/2004 |
8/1/2005 |
100% |
|
Published
|
| Closed |
S0003 |
Carbo/Pac + Tirapazamine vs. Carbo/Pac in Adv. NSCLC; Selected IIIB & IV |
11/15/2000 |
11/15/2002 |
72% |
|
Published
|
| Closed |
SWOG-8412 |
Carboplatin/Cyclophosphamide vs. Cisplatin/ Cyclophosphamide in Patients with Measurable and Non- Measurable (Sub-Optimal) Disease Stages III and IV Ovarian Cancer |
11/25/1985 |
5/1/1989 |
|
|
Published
|
| Closed |
S0518 |
CARCINOID Ph III depot octreotide + either interferon alpha or bevacizumab |
12/1/2007 |
9/1/2012 |
100% |
|
Published
|
| Closed |
SWOG-9342 |
Cardiac Evaluation with MUGA scan at year 5-8 and year 10-11 OR at years 10-14 only |
2/15/1997 |
11/15/2003 |
43% |
|
Published
|
